← All storiesIV · After institution

Feature3 min readInter partes review

If the settlement mentions it, file it.

DTN and Farms Technology settled two inter partes reviews and tried to keep two side agreements out of the record. The patent owner hadn’t signed either, and neither depended on ending the cases. The Board’s answer, now precedential: “any” means “any.” Confidential filing was available, and granted.

2 of 2side agreements had to be filed in DTN, though the patent owner signed neither.

Before you read

An IPR settlement refers to a supply agreement the patent owner didn’t sign. Does the supply agreement have to be filed with the Office?

Part 1 of 7

“Any” means “any”

DTN and Farms Technology settled two IPRs and filed their settlement agreement, as the statute requires. The agreement referred to two other agreements. The parties asked to expunge those from the record. The patent owner wasn’t a party to either, they said, and neither depended on ending the IPRs. The Board denied both requests.

“The term ‘any’ means ‘any.’”
Board, DTN v. Farms Technology, June 14, 2019 (precedential)

Part 2 of 7

What the statute requires

An IPR can be ended by settlement before the Board decides the merits. The settlement must be filed: “Any agreement or understanding between the patent owner and a petitioner, including any collateral agreements referred to in such agreement or understanding, made in connection with, or in contemplation of, the termination of an inter partes review under this section shall be in writing and a true copy … filed in the Office.”

A collateral agreement is a side deal, such as a license, supply contract or covenant, that sits alongside the main settlement. A true copy is a complete and accurate one.

Test yourself. Each card describes an agreement; tap to see whether DTN requires filing it.

Must it be filed?

0 of 5 revealed

Part 3 of 7

Two arguments that failed

What the parties argued, and the answer

1Argument one: the owner didn’t sign them

The argument
Only collateral agreements between the patent owner and a petitioner must be filed.

The BoardThe settlement was between owner and petitioner and referred to both side agreements. Under the statute, that is all it takes.

2Argument two: they don’t depend on ending the IPRs

The argument
One side agreement never mentioned the proceedings; the other mentioned them only in its recitals.

The BoardThe “in contemplation of” requirement applies to the settlement agreement. Collateral agreements “need only be ‘referred to’ in the Settlement Agreement to qualify under § 317(b), which they undisputedly are.”

The Board denied the motions to expunge, granted the joint requests to treat the agreements as confidential, and terminated both IPRs.

Part 4 of 7

Confidential, not secret

Confidential treatment comes from the statute. On request, a filed agreement “shall be treated as business confidential information, shall be kept separate from the file of the involved patents, and shall be made available only to Federal Government agencies on written request, or to any person on a showing of good cause.”

Confidential treatment under § 317(b)

It means

  • Kept separate from the patent files
  • Treated as business confidential information
  • Granted in DTN on joint request

It doesn’t mean

  • Never seen: federal agencies can get it on written request
  • Never seen: anyone can get it on a showing of good cause
  • That a reference can be dropped from the settlement to avoid filing

Deleting a reference is not a substitute for complying. The documents filed have to reflect the actual settlement arrangement.

Part 5 of 7

Settling with an amendment pending

Kokusai v. ASM, an informative 2019 decision, shows a related limit. The parties settled while the owner’s unopposed motion to amend was pending, and asked the Board to grant it in part.

The tidy ending

The tempting reading

Both sides agree, so the Board will grant the amendment as part of the settlement.

Source

Part 6 of 7

What to do

Choose your side.

Settlement disclosure, before you sign

0 of 5 reviewed

  • Expect every referenced side deal to be filed, whoever signed it.
  • Don’t expect a settlement to get a pending amendment granted. Use reissue or reexamination if you need the claims.

Part 7 of 7

Cuts the other way

Both decisions date from 2019. DTN’s facts involved side agreements the patent owner hadn’t signed; its holding is broad, but it was applied to those facts. And settlements are a smaller share of how IPRs end than they were.

Settlements as a share of concluded proceedings

FY2022
27%
FY2023
30%
FY2024
32%
FY2025
26%
FY2026
16%

Settlements divided by concluded proceedings: denied institution, settled, dismissed, requested adverse judgment and final written decision, excluding joined cases. Institution denials are in the denominator, so more denials alone would push the rate down. The drop doesn’t by itself show parties are less willing to settle.

Source

The takeaway

Put disclosure in the closing plan. The deal can be done while the Office filing is still incomplete.

Sources

  1. S31DTN, LLC v. Farms Technology, LLC, No. IPR2018-01412, Paper 21 (P.T.A.B. June 14, 2019) (precedential). Official source ↗
  2. S33Kokusai Electric Corporation v. ASM IP Holding B.V., No. IPR2018-01151, Paper 38 (P.T.A.B. August 20, 2019) (informative). Official source ↗
  3. S13Federal patent statutes, 35 U.S.C. §§ 253(a), 303(a), 311–315, 317 and 321–325. Reproduced in MPEP Appendix L (currency date stated by the appendix: Jan. 31, 2024). Official page ↗
  4. S48USPTO, PTAB Trial Statistics, September 2026 (FY2026: Oct. 1, 2025 to Sept. 30, 2026). Data source ↗
  5. S49USPTO, PTAB Trial Statistics, August 2026 (settlements slide, FY2022 to FY2026 year to date). Data source ↗

Precedential decisions bind the Board within their designated scope. Informative decisions show the Office’s reasoning but do not bind the Board. Court opinions are cited for what they decided; later history was checked on the date shown above.

Changes (5)
  • Settlement figure confirmed: the USPTO’s slide shows 26% for FY2025 and 27% for FY2022; FY2026 is 16% (Trial Statistics, Aug and Sept 2026, slide 10). A draft correction to 27% had the years reversed (Glossy re-check, Oct 16, 2026).
  • New interactive “must it be filed?” quiz built from the decision’s facts, with an honest “not addressed” card.
  • Removed the speculation that DTN’s “practical cost may be small”; replaced with what the statute says confidential treatment does and doesn’t do (Muse flagged this).
  • Added from the reviewed note 14: don’t delete a reference to dodge disclosure; the filed documents must reflect the actual arrangement.
  • Removed an emoji code (“:left_right_arrow:”) and an internal package reference (“FINAL #15”) from the graphic spec.
General information about published decisions, not legal advice. Reading it does not create an attorney-client relationship.
1 / 7